HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 06-06-2015, 09:01 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Arrow Dr. Slamon describes results of genomic seqncng to determine who benefits from adding

everolimus (an mTor inhibitor which ffeecets the PI3k pathway) to herceptin in Stage IV patients

http://meetinglibrary.asco.org/content/112020?media=vm
Lani is offline   Reply With Quote
Old 06-07-2015, 03:44 AM   #2
sarah
Senior Member
 
Join Date: Sep 2005
Location: france
Posts: 1,648
Re: Dr. Slamon describes results of genomic seqncng to determine who benefits from ad

yes interesting and here's more on the subject:
http://www.ascopost.com/ViewNews.aspx?nid=20674
sarah
__________________
sarah is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:22 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter